Camptothecin

Camptothecin

SCHEMBL4304557

CC[C@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 18/20 1.00
ALDH1A1 P00352 4/20 1.00
MEN1 O00255 4/20 1.00
KMT2A Q03164 4/20 1.00
SMN1; SMN2 Q16637 4/20 1.00
KDM4E B2RXH2 3/20 1.00
GLA P06280 3/20 1.00
TP53 P04637 2/20 1.00
HPGD P15428 2/20 1.00
CYP3A4 P08684 2/20 1.00
HBB P68871 2/20 1.00
STAT6 P42226 1/20 1.00
CHEK1 O14757 1/20 1.00
HDAC3 O15379 1/20 1.00
ABCC4 O15439 1/20 1.00
GMNN O75496 1/20 1.00
LMNA P02545 1/20 1.00
CYP1A2 P05177 1/20 1.00
HNRNPA1 P09651 1/20 1.00
GAA P10253 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Camptothecin SCHEMBL29360250 1.00 TOP1 (1.00) TOP1ALDH1A1MEN1KMT2ASMN1; SMN2
Camptothecin SCHEMBL29351099 1.00 TOP1 (1.00) TOP1ALDH1A1MEN1KMT2ASMN1; SMN2
Camptothecin SCHEMBL788063 1.00 TOP1 (1.00) TOP1ALDH1A1MEN1KMT2ASMN1; SMN2
Camptothecin SCHEMBL28057307 1.00 TOP1 (1.00) TOP1ALDH1A1MEN1KMT2ASMN1; SMN2
Camptothecin SCHEMBL29369924 1.00 TOP1 (1.00) TOP1ALDH1A1MEN1KMT2ASMN1; SMN2
Camptothecin SCHEMBL6038 1.00 TOP1 (1.00) TOP1ALDH1A1MEN1KMT2ASMN1; SMN2
Camptothecin SCHEMBL2298909 1.00 TOP1 (1.00) TOP1ALDH1A1MEN1KMT2ASMN1; SMN2
Camptothecin SCHEMBL548833 0.99 TOP1 (0.98) TOP1ALDH1A1MEN1KMT2ASMN1; SMN2
Camptothecin SCHEMBL17112859 0.99 TOP1 (0.98) TOP1ALDH1A1MEN1KMT2ASMN1; SMN2
Camptothecin SCHEMBL3117386 0.99 TOP1 (0.98) TOP1ALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11007271-B2 Anticancer drug conjugates Ariel Scientific Innovations Ltd. (IL) 2021-05-18 US disclosed
US-20190224328-A1 ANTICANCER DRUG CONJUGATES Ariel Scientific Innovations Ltd. (IL) 2019-07-25 US disclosed
EP-2084178-B1 PEPTIDE-CYTOTOXIC CONJUGATES IPSEN PHARMA SAS (FR) 2011-12-07 EP disclosed
EP-1856124-B1 NEW SYNTHESIS OF A CAMPTOTHECIN SUBUNIT HOFFMANN LA ROCHE (CH) 2011-11-02 EP disclosed
WO-2009129395-A1 CATIONIC LIPIDS AND USES THEREOF ABBOTT LABORATORIES (US) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190224328-A1 ANTICANCER DRUG CONJUGATES BCR, MCL1, TP53 TOP1 32/4885ALDH1A1 359/4885MEN1 2225/4885
US-11007271-B2 Anticancer drug conjugates BCR, MCL1, TP53 TOP1 32/4885ALDH1A1 359/4885MEN1 2225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.